$527 Million is the total value of ATP Life Science Ventures, L.P.'s 2 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | $391,802,000 | +1.9% | 16,786,713 | 0.0% | 74.38% | -3.4% | |
| AKRO | Akero Therapeutics, Inc. | $134,947,000 | +17.5% | 5,415,203 | 0.0% | 25.62% | +11.4% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-07-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Stoke Therapeutics, Inc. | 6 | Q1 2021 | 82.1% |
| Akero Therapeutics, Inc. | 6 | Q1 2021 | 25.6% |
| None | 3 | Q4 2021 | 0.0% |
| Chinook Therapeutics, Inc. | 2 | Q1 2021 | 7.0% |
View ATP Life Science Ventures, L.P.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC.Sold out | January 21, 2022 | 0 | 0.0% |
| Akero Therapeutics, Inc. | June 29, 2021 | 37,555 | 0.1% |
| Stoke Therapeutics, Inc. | June 29, 2021 | 36,943 | 0.1% |
| Akero Therapeutics, Inc. | July 14, 2020 | 5,830,203 | 17.2% |
| Cerecor Inc. | February 12, 2016 | 595,436 | 6.9% |
| Dermira, Inc. | February 12, 2016 | ? | ? |
View ATP Life Science Ventures, L.P.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-21 |
| SC 13G/A | 2022-01-21 |
| 13F-HR | 2021-10-20 |
| 13F-HR | 2021-08-04 |
| 4 | 2021-06-30 |
| 4 | 2021-06-30 |
| SC 13D/A | 2021-06-29 |
| SC 13D/A | 2021-06-29 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-03 |
View ATP Life Science Ventures, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.